US Genomics and Lahey to Explore miRNA-based Urologic Cancer Biomarkers for Dx Development

US Genomics and Lahey to Explore miRNA-based Urologic Cancer Biomarkers for Dx Development
By Doug Macron
October 26, 2006
RNAi News
The deal, US Genomics? second involving miRNA-based diagnostics, gives the firm the right to commercialize products, which is something it doesn?t have under its first alliance, with Rosetta Genomics.
Paid subscription is required to view article.
Comments: 0
Votes:18